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CASE PRESENTATIONS
Patient 1. A 32-year-old man, undergoing hemodialysis for approxi-
mately seven months because of end-stage renal disease due to focal
glomeruloscierosis, developed an asymptomatic increase in serum ALT
(160 lU/liter) and AST (230 lU/liter) levels (upper limit of normal for
ALT and AST, 40 lU/liter). The HBsAg and other hepatitis B virus
(HBV) serologic markers were negative. Because the ALT and AST
remained elevated for longer than six months, liver biopsy was performed
seven years ago. Histologic examination revealed lobular activity without
fibrosis and thus mild chronic hepatitis. interpreted according to the most
recently adopted criteria for grading (intensity of necroinfiammatory
activity) and staging (fibrosis) of chronic hepatitis [11, the histologic
findings were classified as grade 8 and stage 0 (maximum score for grading
and staging, 18 and 6 respectively). The histologic picture was compatible
with that of non-A, non-B hepatitis. This diagnosis was confirmed later,
when antibody against hepatitis C virus (anti-HCV) was detected in a
stored serum sample.
Following a six-month course of treatment with r-INF-a (3 MU three
times/week), the ALT and AST returned to normal. Three months later,
the patient received a kidney graft donated by his mother. His immuno-
suppressive regimen consisted of prednisolonc, azathioprine, and cyclo-
sporine A. On the 10th post-transplant day, he experienced an acute
rejection episode that was successfully treated with intravenous pulse
methylprednisolone (1 g daily for three consecutive days). Upon discharge
from the hospital, the patient's serum creatinine was 1.6 mg!dl, but over
the ensuing years, his graft function gradually deteriorated, culminating in
chronic rejection (latest serum creatinine, 6.5 mg/dl). After transplanta-
tion, the serum anti-HCV remained repeatedly positive and the liver
biochemical tests persistently normal. Two successive liver biopsies per-
formed two and five years after transplantation (33 and 69 months after
the first biopsy), showed no hepatitis lesions (grade 0, stage 0) and
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minimal hepatitis without fibrosis (grade 1, stage 0) respectively. Through-
out this period, the serum HCV RNA was positive; the bDNA was 45.89
HCV Eq/mi X i0 at the first liver biopsy and 68.6 HCV Eq/mi X i0 at
the second. Recent determination of the HCV genotype showed that the
patient was infected with genotype 3a.
Patient 2. A 52-year-old man with end-stage renal disease of unknown
cause started hemodialysis nine years ago. While on hemodialysis, he
exhibited several intermittent, short-lived episodes of slight increases in
the serum ALT, AST, and yGGT. The HBsAg and other HBV markers
were consistently negative. Six years ago, he received a cadaveric kidney.
Immediately before transplantation, he was found to be anti-HCV posi-
tive. His immunosuppressive regimen consisted of prednisolone and
cyciosporine. The patient's immediate post-transplantation period was
uneventful, and upon discharge from the hospital, his serum creatinine
was 1.5 mg/di.
Two years later, a renal allograft biopsy performed because of a gradual
increase in serum creatinine and the appearance of proteinuria (2.5 g/24
hr) revealed chronic rejection. His latest serum creatinine and 24-hour
urinary protein excretion (two months ago) were 3.5 mg/dl and 5.0 g
respectively. After transplantation, the anti-HCV remained positive and
the liver enzymes were consistently elevated. Fourteen months after
transplantation, the serum ALT was 90 lU/liter; AST, 94 lU/liter; yGGT,
350 lU/liter (upper limit of normal, 32 lU/liter); alkaline phosphatase, 400
lU/liter (upper limit of normal, 306 IU/hter), and HCV RNA was
detectable in the serum. Liver uitrasonography showed no evidence of
extrahepatic cholestasis. A liver biopsy revealed moderate chronic hepa-
titis characterized mainly by lobular activity (grade 9); fibrosis was minimal
(stage 1). Two years ago, the liver biochemistry was unchanged, but the
HCV RNA was still positive, and the serum bDNA was 1.75 HCV
Eq/mi X iO. A second liver biopsy was performed. Compared to the
previous one, this biopsy showed that although the degree of activity had
decreased slightly (grade 8), fibrosis was now prominent (stage 4). Four
months ago (slightly longer than 5.5 years after transplantation and 1.5
years after the second liver biopsy), the patient presented with ascites and
gross edema of the legs. Serum ALT, AST, yGGT, and alkaline phospha-
tase were 74 IU/hter, 50 lU/liter, 304 lU/liter, and 450 lU/liter, respec-
tively; serum biliruhin was 1.2 mg/dl, and total plasma proteins were 5.3
g/dl (albumin, 2.6 g/di; globulin, 1.1 g/di). Serum bDNA was 3.5 HCV
Eq/mi >< iO. Color Doppler ultrasonography of the liver showed minimal
dilation of the portal vein without signs of collateral circulation. Following
a diuretic-induced remission of the ascites, a third liver biopsy revealed a
further reduction in necroinfiammatory activity (grade 7), a further
increase in fibrosis (stage 6), and early signs of cirrhosis. Recent determi-
nation of the HCV genotype showed that the patient was infected with
genotype lb.
DISCUSSION
DR. GREGORY G. VOSNIDES (chief Division of Nephrolo,
Laiko General Hospital, Athens, Greece): These two patients
illustrate some of the problems encountered in HCV-infected
renal transplant recipients. At the same time, these patients
represent two extremes of a wide spectrum of possibilities regard-
ing the outcome of liver disease in this group of patients.
Although both patients were viremic, the first developed very mild
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Fig. 1. Genetic organization of the HCV genome and it polyprotein. Properties and function of the individual structural and non-structural pro-
teins.
liver disease, whereas in the second, aggressive liver disease led to
cirrhosis.
The development and refinement of molecular biology tech-
niques ended our previous ignorance regarding the causative
agent of non-A, non-B hepatitis (NANBH) and lcd to the
identification of HCV as its primary cause. Hepatitis C virus was
cloned in 1989 from complementary DNA (cDNA) extracted
from the plasma of chimpanzees with infectious NANBH [2].
Subsequently, HCV was established as the causative factor in
most cases of NANBH (80% to 90%) [3, 4]. Over the next few
years, intensive research led to the characterization of the entire
HCV genome, recognition of its genetic variability, development
of tests for antibody as well as qualitative and quantitative
detection of the viral genome, and knowledge about the epidemi-
ology, natural history, and treatment of HCV infection.
Hepatitis C virus infection has become a common part of
everyday clinical nephrology. Apart from occurring frequently
among dialysis and renal transplant patients, HCV infection often
is accompanied by cryoglobulinemia and some forms of immuno-
logically mediated renal disease. In this Forum I will highlight,
from a clinical point of view, our current state of knowledge
regarding HCV infection in renal transplant recipients.
Molecular biology of HCV
Hepatitis C virus has been identified and characterized exclu-
sively by means of molecular biology techniques. It is a small,
lipoid-enveloped, single-stranded, positive-sense RNA virus as-
signed to the family of flaviviridae [5]. Its genome consists of
about 9500 nucleotides [2] containing a single, large translational
open-reading frame (ORF) (Fig. 1). Preceding the 5' end and
following the 3' end of the ORF, a number of nucleotides are
present, comprising the untranslated (UT) regions of the genome
[6, 71. The UT region at the 5' end is highly conserved and
contributes to the translation of the viral genome [8]. The ORF
encodes a large polyprotein precursor of about 3010 aminoacids
that is post-translationally cleaved to produce the structural and
nonstructural polypeptides of the virus [6—10]. The structural
regions at the amino-terminal end of the genome encode the core
(C) protein (p22) and the two envelope glycoproteins El (gp35)
and E2/NSI (gp72). These regions are followed by four regions
(NS2-NS5) that code for the nonstructural proteins. The function
of the nonstructural proteins has not yet been fully elucidated, but
it seems that they take part in virus replication and code for
proteases (NS2, N53), helicase (NS3), and RNA-dcpendent RNA
polymerase (NS5) [9, 10]. The HCV genome exhibits considerable
nucleotide sequence heterogeneity, which is not evenly distrib-
uted. The 5' terminal UT region is the most highly conserved
(92% nucleotide homology), the C and NS3 regions are relatively
well conserved (81% and 70% nucleotide homology), and the
other regions are less conserved (26% to 66% nucleotide homol-
ogy) [10]. The extreme amino terminal end of the E2 envelope
glycoprotein exhibits extensive hypervariability (hypervariable re-
gion) [10, 11]. Frequent mutations in this region explain, at least
partially, why in HCV infection immune response is usually
ineffective and why production of antibodies against HCV is not
followed by clearance of the virus and immunity (immune escape)
[10].
The nuelcotide sequence heterogeneity of the genome led to
the recognition of different HCV genotypes. The different classi-
fications and nomenclatures assigned to the genotypes have
caused considerable confusion. Hopefully, a recent consensus
nomenclature, based on a sequence analysis of the NS5 region
proposed by Simmonds and 45 other researchers worldwide [12],
will end the confusion. According to this newer classification, a
sequence similarity of less than 72% with any known sequence is
considered evidence for the existence of a new HCV type,
whereas a maximum sequence similarity of 75% to 86% is
considered evidence for a new subtype. The known types are
numbered starting from 1, and the subtypes are classified as
a,b,c.. . in order of discovery.
Diagnostic tests for HCV infection
The detection of anti-HCV antibodies and viral nucleic acid in
the serum are currently the only means by which HCV infection
can be diagnosed. The first test used for detecting anti-HCV was
the so-called "first-generation" enzyme-linked immunosorbent
assay (ELISA-1) [13]. This assay detects antibodies to the recom-
binant antigen C100 that is part of the NS4 region of the HCV
genome. The low sensitivity and specificity of this test [3] brought
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about the development of the more sensitive and specific second-
generation ELISA (ELISA-2) test, which detects antibodies to
two additional recombinant proteins derived from the capsid
(C22) and the NS3 region (C33c) of the HCV genome [141. The
third-generation ELISA test (ELISA-3), which includes an addi-
tional antigen from the NS5 region, is even more sensitive [15, 161
(Fig. 2). Moreover, a supplementary assay, the second-generation
recombinant immunoblot assay (RIBA-2), which detects antibod-
ies to the 5-1-1, C100, C33, and C22 proteins, is used to confirm
positive anti-HCV ELISA tests [171. The RIBA-3 test detects an
additional antibody (to the recombinant NS5 antigen) [10].
The absence of a direct assay for antigenemia makes detecting
the HCV genome necessary for ascertaining the presence of
viremia. However, since viral titers in HCV infection are too low
to be directly detected by conventional nucleic acid hybridization
techniques, the viral nucleic acid must be amplified. Detection is
accomplished by reverse transcription (RT) of the hepatitis C
virus RNA to cDNA and its amplification through polymerase
chain reaction (PCR) [18—20]. The 5' UT highly conserved region
of the HCV genome is the target of current PCR techniques. As
RT-PCR can detect viremia shortly after acquisition of HCV
infection and prior to the appearance of anti-HCV [211, RT-PCR
is the only definitive test for diagnosing HCV infection. The
polymerase chain reaction technique is very sensitive and specific,
provided that strict measures for the avoidance of contamination
(false-positive results) and storage (false-negative results) of the
blood samples are applied [22].
Quantitative assessment of serum hepatitis C virus RNA load is
obtained with the branched-chain DNA (bDNA) assay, in which
synthetic DNA molecules are used, and the signal probe (instead
of the viral nucleic acid) is amplified [23—25]. The specific
hybridization of synthetic oligonucleotides to the 5' UT region
and the core genes of the hepatitis C virus RNA allows for the
RNA to be captured onto the surface of a well. Synthetic bDNA
molecules and multiple copies of an alkaline-phosphatase-linked
probe are hybridized to the immobilized complex (signal amplifi-
cation). Detection is achieved by incubating the complex with a
chemiluminescent substrate and by measuring the light emission
generated by the bound alkaline phosphatase. Light emissions are
proportional to the amount of hepatitis C virus RNA present in
the sample. Hepatitis C virus RNA is quantified by comparing the
light emission of the test sample to that of a standard curve
defined by light emissions from known quantities of hepatitis C
virus RNA. Although the branched-chain DNA assay is much less
sensitive than is PCR (the lower limit of detection is 350,000 and
2,000 copies of HCV RNAJm1 for bDNA and PCR, respectively),
the bDNA assay is less laborious and less time consuming, and it
exeludes false-positive results due to contamination [23].
HCV infection in dialysis patients
Although this Forum focuses on the problem of HCV infection
in renal transplant recipients, a brief digression to HCV infection
in dialysis patients is useful because these patients constitute the
pool of candidates for renal transplantation. Further, most renal
transplant recipients acquire HCV infection while they are on
dialysis.
The prevalence of anti-HCV-positive hemodialysis patients
varies considerably among countries. An assessment by the Euro-
pean Renal Association (ERA)-European Dialysis and Trans-
plant Association (EDTA), using information taken from the
1993 center questionnaire of patients undergoing hemodialysis in
all European and Mediterranean countries, showed that 17.7%
were anti-HCV positive [26]. In the majority of the countries
bordering the Mediterranean sea, the prevalence ranges between
20% and 30% (Portugal, 29%; Spain, 25%; France, 19%; Italy,
27%; Greece, 24%; Turkey, 30%). Exceptions are Egypt (44%),
Israel, (14%), and Lebanon (5%). In some Eastern European
countries, the percentage of anti-HCV-positive patients is very
high as well (Poland, 29%; Romania, 35%). Other European
countries have lower prevalences (UK, 2%; Sweden, 8%; Ger-
many, 7.5%; Austria, 10%). In 1994, the incidence of anti-HCV-
positive hemodialysis patients in Europe was 29 new cases per
thousand patients/year [271. In the United States, a nationwide
survey of hemodialysis centers performed in 1991 by the Health
Care Financing Administration in conjunction with the Centers
for Disease Control and Prevention reported the percentage of
NANBH to be 0.5% [28]. The prevalence of anti-HCV patients in
selected hemodialysis units in the United States ranges from 15%
to 25% [29, 30]. Also, in a multicenter prospective study including
499 patients from 11 hemodialysis units from different geographic
regions in the United States, anti-HCV was detected in 10% of
the patients, but the prevalence ranged widely (2% to 26%) [31].
Over the past few years, it has become clear that the vast majority
(73% to 98%) of ELISA-2, ELISA-3, and/or RIBA-2- or -3-
positive hemodialysis patients are viremic [32—37] and that the
viremia persists [37]. This finding implies that most anti-HCV-
positive hemodialysis patients awaiting transplantation are vire-
mic. It also has become clear that anti-HCV antibodies develop
long after the occurrence of viremia [38]. In two recent reports,
hepatitis C virus RNA was detectable in the serum of 9% to 13%
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Fig. 2. Structural (c22) and non-structural (5-
1-1, clOO, c33c, NS5) proteins of the HCV used
in first (1), second (2), and third (3) generation
enzyme immunoassays (ELISA) for HCV
antibody detection.
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of anti-HCV-negative patients [39, 40]. It is therefore likely that
some viremic but anti-HCV-negative hemodialysis patients un-
dergo transplantation. Moreover, Oesterreicher et a! recently
reported that in hemodialysis patients without anti-HCV or HCV
RNA in the serum, HCV RNA can be detected in peripheral
blood mononuclear cells [41]. Blood transfusions [29, 30, 33—35,
42, 43], duration of hemodialysis [31, 32, 34, 35, 44—47], and
intravenous drug abuse [29, 30, 33] have been incriminated as
major risk factors for acquisition of HCV infection by patients
undergoing hemodialysis. Although several studies have shown a
highly significant association between the number of blood trans-
fusions and the prevalence of anti-HCV among hemodialysis
patients [29, 30, 33—35, 42, 43], other studies failed to establish
such a relationship and showed that duration of hemodialysis is
the major risk factor for acquisition of HCV infection [31, 32,
44—47]. Furthermore, antibodies to HCV can be detected in a
substantial proportion (7% to 27%) of non-transfused hemodial-
ysis patients [31, 42, 48]. The prevalence of anti-HCV is much
lower among continuous ambulatory peritoneal dialysis (CAPD)
patients (0% to 10%) compared with hemodialysis patients [49—
53]. Recently, a large epidemiologic study in Spain (81 centers,
4684 patients) showed that, apart from the modality of dialytic
treatment (hemodialysis versus chronic ambulatory peritoneal
dialysis), the location of hemodialysis also greatly influences the
prevalence of anti-HCV-positive patients (hospital hemodialysis,
34.8%; satellite hemodialysis, 25.4%; home hemodialysis, 6.8%)
[531. These data indicate that, at present, we lack knowledge
about several factors (intradialytic, intercenter, environmental,
nosocomial, etc.) that might contribute to the transmission of
HCV in the dialysis setting. Until these factors are elucidated, the
application of effective preventive measures does not seem feasi-
ble.
Transmission of HCV infection via organ transplantation
Transplantation of organs from HCV-infected donors is an-
other source of HCV infection in renal transplant recipients
[54—62]. Policies regarding utilization of organs from anti-HCV-
positive donors vary considerably among centers. For example, in
the United States, a survey of 147 transplant centers showed that
54% of the centers do not utilize kidneys from anti-HCV-positive
donors, 24% transplant such kidneys into anti-HCV-positive
recipients only, 5% transplant these kidneys irrespective of the
anti-HCV status of the recipient, and 17% of the centers do not
have a specific policy [63].
Prevalence of HCV infection among cadaver donors. The preva-
lence of HCV infection among cadaver donors varies widely
among different centers. Recently, in a national collaborative
study of 3078 cadaver organ donors from eight organ procurement
organizations in the United States, the prevalence of ELISA-1,
ELISA-2, and hepatitis C virus RNA-positive donors was 5.1%,
4.2%, and 2.4%, with a range from 1.5% to 16.7%, 2.3% to 8.3%,
and 0.8% to 4.2%, respectively [54]. In another study, of the 484
cadaver donors screened, 89 (18%) were identified as ELISA-1
positive, of whom only 33 (6.8%) were also RIBA positive [55, 601.
These inconsistencies have been attributed to differences in the
geographic prevalence of HCV infection [54, 55, 641. Roth et al
found that the majority of anti-HCV-positive organ donors harbor
active HCV infection, since in their study, liver tissue from 24
RIBA-positive donors showed chronic active hepatitis in 16
(67%), chronic persistent hepatitis in 2 (8%), and normal liver in
6 (25%) [55, 60]. Hepatitis C virus RNA was present in the serum
of 88% (14/16) of the donors with chronic active or persistent
hepatitis and in none of those with normal liver tissue [55]. Male
gender, history of alcohol abuse, history of drug abuse, blood
alcohol levels greater than 100 mg/dl, presence of potentially
abused drugs in the blood, and detection of anti-HBc or anti-
cytomegalovirus antibodies are important risk factors for the
presence of anti-HCV in the serum of organ donors [54]. Organ
donors with an absence of hepatitis-B-positive serology, normal
liver function tests, and no history of drug abuse or homosexuality
have been characterized as low-risk donors [56, 57]. However, the
United States collaborative study provided strong evidence
against the existence of "low-risk" donors, as no differences were
found in the clinical and biochemical characteristics between
ELISA-2-positive donors with and without detectable hepatitis C
virus RNA in the serum [54].
Incidence of HCV transmission via organ transplantation. In the
United States national collaborative study, a comparison drawn
between recipients of organs from ELISA-2-positive donors with
and without hepatitis C virus RNA (47 and 23 recipients, respec-
tively) showed that, post transplantation, the prevalence of vire-
mia and ELISA-2 seropositivity was significantly higher in recip-
ients of organs from ELISA-2-positive/HCV-RNA-positive
donors than in recipients of organs from ELISA-2-positive/HCV-
RNA-negative donors (100% versus 43%, P < 0.001 for HCV
RNA, and 73% versus 25%, P = 0.01 for ELISA-2) [54]. In the
same study, a significantly higher (P = 0.04) prevalence of
post-transplantation liver disease (defined as an increase in serum
ALT to more than 2.5 times the upper limit of normal) was
observed in recipients of organs from ELISA-2-positive/HCV-
RNA-positive donors (22/47, 47%) than in recipients of organs
from ELISA-2 positive/HCV-RNA negative donors (5/23, 22%).
No significant differences were observed in the incidence of death
and graft loss.
A striking feature regarding the incidence of transmission of
hepatitis C virus via organ transplantation is the major differences
among centers. In one of the earlier studies by Pereira et at,
among 26 recipients of organs from 11 anti-HCV-positive donors
(of whom 9 were HCV-RNA positive), the prevalence of HCV-
RNA-positive recipients increased significantly after transplanta-
tion (7/26, 27% versus 23/24, 96%; P < 0.001) [58]. Moreover, all
patients who were HCV-RNA negative before transplantation
(13/13), and for whom post-transplantation serum samples were
available, tested positive for HCV RNA after receiving an organ
from an HCV-positive donor. In a more recent controlled study,
Pereira and colleagues compared the outcome of 29 patients who
received organs from 13 anti-HCV-positive donors with that of 74
patients who received organs from 37 donors who were randomly
selected from a pool of 703 anti-HCV-negative donors [59]. Post
transplantation, among recipients of organs from anti-HCV-
positive donors, 67% (16/24) were ELISA-2 positive, and 96%
(23/24) were HCV-RNA positive, whereas among organ recipi-
ents from anti-HCV-negative donors, only 20% (9/45) were
ELISA-2 positive, and only 18% (8/44) were HCV-RNA positive
(P < 0.001). In the same study, the prevalence of post-transplan-
tation liver disease was higher in recipients of organs from
anti-HCV-positive donors than in recipients of organs from
anti-HCV-negative donors (16/29, 55% versus 11/69, 16%; P <
0.001). The risk of post-transplantation liver disease was 4.4-fold
higher in recipients of organs from anti-HCV-positive donors. No
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differences were observed in the incidence and causes of death or
graft loss, but the post-transplantation followup period was short
(median followup, 42 months and 49 months, respectively). Other
investigators have observed a much lower incidence of transmis-
sion of HCV infection by organ transplantation than did Pereira
and coworkers [54, 58, 591. For instance, Roth et al found that
post transplantation, of 46 1-IBsAg-negative recipients of a kidney
from a RIBA-positive donor, 33 (72%) maintained normal liver
function, whereas only 13 (28%) developed liver disease (3 with
acute, self-limited hepatitis at 17.5 9 weeks, and 10 with chronic
liver dysfunction at 14.1 8 weeks) [55, 601. In these studies, 13
of 15 (87%) seronegative recipients of a kidney from a RIBA-
positive donor remained anti-HCV negative one year after trans-
plantation; 6 of the 13 (46%) recipients with post-transplantation
liver disease remained HCV seronegative at followup testing [55,
60]. Furthermore, Roth et al observed post-transplantation liver
disease in only 9 of 27 (33%) kidney and heart recipients who
received organs from 15 donors, all of whom had either chronic
active or chronic persistent hepatitis, and 13 of whom were
HCV-RNA positive [55]. Likewise, these authors found biochem-
ical evidence of post-transplantation liver disease in only 6 of 20
(30%) recipients of a kidney from an HCV-RNA-positive donor;
the remaining 14 (70%) maintained normal hepatic biochemis-
tries during a mean followup of 27 8 months [55]. Moreover, in
a recent editorial, Roth refers to his center, Jackson Memorial
Hospital in Miami, Florida, where only 8 of 14 (57%) HCV-RNA-
negative recipients became HCV-RNA positive after receiving a
kidney from an HCV-carrier donor [61]. Roth's results are almost
identical to those of Tesi et al, who found that of 37 HCV-RNA-
negative recipients of a kidney from an HCV-RNA-positive
donor, only 21(56%) became HCV-RNA positive after transplan-
tation [62]. The same study reported that although the incidence
of hepatitis (defined as an elevation of ALT  100 units for more
than 14 days) was higher in recipients of organs from HCV-RNA-
positive donors (38%) than in recipients of organs from HCV-
RNA-negative donors (22%), this difference did not reach statis-
tical significance. Further, neither fulminant hepatitis nor rapid
progression to cirrhosis was observed. However, this study too had
a short followup period (average, 612 days; range, 62 to 1154
days). In another study, none of 6 recipients of a kidney from an
HCV-RNA-positive donor had detectable hepatitis C virus RNA
in the serum 36 to 40 months after transplantation [63].
Roth has offered some hypotheses regarding the differences in
the incidence of hepatitis C virus transmission via organ trans-
plantation [64], but definite explanations are not yet available.
One factor that cannot be ignored as a possible explanation,
however, is the method used for organ preservation. The rate of
transmission of hepatitis C virus via organ transplantation has
been much higher in centers using slush preservation [58] than in
centers using pulsatile perfusion [55, 60, 62, 651. Zucker and
colleagues studied the effect of standard pulsatile renal preserva-
tion, and variations of it, on the number of viral copies in kidneys
procured from HCV-infected donors [66]. Standard pulsatile
perfusion eliminated 75% of the virus in 20 hours. Modification of
this procedure by the inclusion of a second pulsatile perfusion
eliminated more than 99% of the virus from the kidney. The same
study reported that adding a high-flow-rate ultrafilter with a
molecular cut-off of 300,000 daltons in series to the apparatus
eliminated the virus from the perfusion solution in less than 2
hours. Thus it is likely that modifications in organ preservation
techniques could reduce the incidence of transmission of hepatitis
C virus by organ transplantation. It is clear that larger studies of
this issue are needed.
Transplantation of organs from HCV-infected donors into HCV-
infected recipients. In a number of centers, kidneys from anti-
HCV-positive donors are transplanted into recipients who are
known to be anti-HCV positive prior to transplantation. A
prospective Spanish multicenter study discerned no significant
differences between 24 ELISA-2-positive recipients of kidneys
from ELISA-2-positive donors (followup, 26 8 months) and 40
ELISA-2-positive recipients of kidneys from ELISA-2-negative
donors (followup, 30 10 months) in a variety of parameters: the
prevalence of mild liver abnormalities (21% versus 33%), chronic
liver disease (8% versus 8%), presence of serum HCV RNA (96%
versus 77%), patient survival (100% versus 98%), and graft
survival (96% versus 93%) [67]. Although the results of this study
are encouraging, they should be interpreted with caution because:
(1) animal [681 as well as clinical [691 studies have shown that
previous infection with hepatitis C virus protects neither from
reinfection with a different strain of the virus, or even the same
strain, nor from reappearance of liver disease. (2) The followup
period of the study was short. Therefore, any adverse effects might
not have manifested themselves yet, although, after an extension
of the followup to 40 9 months and 49 11 months [70], no
significant differences were seen. (3) Four of the five ELISA-2-
positive/HCV-RNA-negative recipients of kidneys from anti-
HCV-positive donors became HCV-RNA positive after trans-
plantation. This change might represent transmission of hepatitis
C virus from anti-HCV-positive donors to anti-HCV-positive but
HCV-RNA-negative recipients, although reactivation of the
host's hepatitis C virus cannot be excluded. The Spanish group
suggested as a safer strategy the testing for HCV RNA of all
anti-HCV-positive potential recipients on the waiting list, and
allocation of organs from anti-HCV-positive donors only to
recipients who test positive for HCV RNA. Even with this policy,
however, reinfection of the recipients with a different or even the
same genotype of the virus is possible. Therefore, although this
strategy could be considered "safer," I agree with Pereira's
opinion: extensive, controlled, long-term studies evaluating the
outcome of HCV-RNA-positive recipients of organs from HCV-
RNA-positive donors are necessary [711. Such studies should
include detection of genotypes in donors and recipients, before
and after transplantation, to determine whether HCV infection
after transplantation is with the same or different genotype of the
virus. Until those studies have been completed, I believe we
should be cautious about performing such transplantations.
Liver disease after renal transplantation
Liver disease, one of the most important complications of renal
transplantation, significantly contributes to morbidity and mortal-
ity [72—761. Liver disease is defined as acute when abnormal liver
function tests revert to normal within six months of disease onset,
and as chronic when liver function abnormalities persist for longer
than six months [75]. The reported prevalence of liver disease in
renal transplant patients varies from 4% to 38% [75]. In a survey
of 2041 patients reported in the literature, Rao and Anderson
found the mean prevalence to be 16%; more recently, of 915
consecutive patients who underwent renal transplantation be-
tween 1971 and 1990 at their own institution, 180 (20%) and 119
(13%), respectively, were classified as having acute and chronic
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Table 1. Prevalence of anti-HCV-positive renal transplant recipients by
second generation assays
Recipients tested
Total Anti-HCV
Authors no. positive
Boletis et al, 1992 [81] 156 41(26%)
Chan et al, 1993 1821 185 19 (10%)
Roth et al, 1994 [831 641 109 (17%)
Morales ct al, 1993 [84] 327 83 (25%)
Hestin et al, 1995 [85] 378 45 (12%)
Berthoux, 1995 [86] 399 105 (26%)
Pouteil-Noble et al, 1995 [871 1098 235 (21%)
a Numerals in brackets refer to reference numbers
liver disease after transplantation [751. Many factors contribute to
the development of liver disease in renal transplant recipients.
The most common causes of acute liver disease are viral infections
such as cytomegalovirus, Epstein-Barr virus, herpes simplex virus,
and varicella zoster virus. Various drugs, including azathioprine,
cyclosporine, antihypertensive drugs, and lipid-lowering agents,
also can induce acute liver disease [75]. Acute forms of liver
disease usually remit as the viral infection is cleared or the
offending drug is discontinued [75]. In contrast, studies from
different countries have shown that hepatic failure due to chronic
liver disease is the cause of death in 21% [77] and 25% to 27%
[78—80] of renal transplant recipients with functioning grafts for
longer than five and ten years, respectively. In the past, most cases
of chronic liver disease in renal transplant patients were attributed
to hepatitis B virus infection, NANBH, hemosiderosis, or alcohol
abuse. However, over the past few years, as a consequence of the
dramatic reduction in the incidence of hepatitis B virus infection
in patients undergoing hemodialysis and renal transplantation, as
well as the discovery of hepatitis C virus and its identification as
the major cause of NANBH, hepatitis C virus infection has
emerged as the main cause of chronic liver disease in the renal
transplant patient population.
HCV infection in renal transplant recipients
Most HCV-infected renal transplant recipients become in-
fected before transplantation while they are on dialysis, but
hepatitis C virus also can be acquired at the time of transplanta-
tion due to exposure to blood transfusions or organs from infected
donors.
Prevalence of anti-HCJ/ and HCV RNA. The prevalence of
anti-HCV-positive renal transplant recipients varies among cen-
ters. Using an ELISA-2 assay, we found 26% (4 1/156) of our renal
transplant recipients to be anti-HCV positive [81]. This percent-
age is compatible with other studies in which 10% to 26% of
transplant recipients were ELISA-2, anti-HCV positive (Table 1)
[82—87]. The prevalence of anti-HCV-positive patients is influ-
enced by various factors such as race [88] and geographic origin of
the recipient [86], mode of dialytic treatment (hemodialysis versus
chronic ambulatory peritoneal dialysis) [82, 86] and duration of
hemodialysis before transplantation [81, 84, 86, 89, 90], number of
blood transfusions [82, 84, 89], number of previous transplants
[89, 90], and the presence of hepatitis B virus infection [86, 89].
The majority (74% to 95%) of ELISA-2-positive renal transplant
recipients are viremic (HCV RNA is present in the serum) (Table
Table 2. Prevalence of viremia (HCV RNA) among anti-HC V-positive
renal transplant recipients (using second-generation assays)a
Authors
Recipients tested
Anti-HCV
positive
HCV-RNA
positive
-
Boletis et al, 1995 [81]h
Chan et al, 1993 [82]
Roth et al, 1994 [83]
Hestin et al, 1995 [85]
Pouteil-Noble et al, 1995 [87]
- -
37
19
53
45
53
34 (92%)
18 (95%)
39 (74%)
38 (84%)
43 (8 1%)
a RIBA
b Numerals in brackets refer to reference numbers
2) [82, 83, 85, 87, 91], and the viremic state persists in almost all
patients [39, 82, 92].
Implications of HCV infection. Biochemical evidence of liver
disease has been reported in 20% to 70% of ELISA-2- and/or
RIBA-2- and/or HCV-RNA-positive renal transplant recipients
[81, 82, 84, 86, 87, 90]. Furthermore, in the study by Roth et a!, 20
of 39 (51%) HCV-RNA-positive renal transplant patients main-
tained normal liver biochemistry throughout the post-transplan-
tation followup (68.7 28.8 months) [831; Berthoux found an
elevation of ALT in only 23 of 117 viremic patients (20%) [861.
These findings indicate that a considerable number of HCV-
infected renal transplant patients maintain normal liver function
test results and, in some studies, such patients are classified as not
having liver disease. These data, however, should be interpreted
with caution, as liver function tests and liver histology are poorly
correlated. We recently found that 7 of 27 ELISA-2-positive
recipients with abnormal liver function tests (26%) had an
essentially normal liver on histologic examination, whereas 6 of 10
patients with normal liver function tests (60%) had chronic liver
disease [91]. Our findings correspond with those of others [75, 86,
93, 94]. We also found that serum hepatitis C virus RNA is a poor
predictor of liver histology: it was detected in 9 of 10 patients
(90%) with no significant changes, 3 of 3 patients with acute
hepatitis, and 22 of 24 patients (92%) with various histologic
forms of chronic liver disease [91]. We also observed no relation-
ship between the number of viral copies present in the serum and
liver histology (unpublished data). Today's cases are an example
of this. Patient 2, who had histologic evidence of severe liver
disease and cirrhosis, had much lower levels of viremia compared
to Patient 1, who had only very mild liver disease. A "healthy"
carrier state (HCV-RNA-positive, normal liver function test
results, normal liver histology) also has been reported in 8% to
10% of HCV-infected renal transplant recipients [91, 95]. Thus,
data show that in HCV-infected patients, neither anti-HCV nor
liver function tests, viremia, or degree of viremia predict the
presence or severity of liver disease. Liver biopsy is therefore
essential for diagnostic, prognostic and, possibly, therapeutic
purposes. We have adopted this policy in our unit. In the absence
of any contraindications, renal transplant recipients with evidence
of hepatitis C virus infection undergo liver biopsy regardless of the
results of their liver function tests.
Renal transplant recipients with HCV infection develop a wide
spectrum of hepatic histopathologic lesions [1, 83—87, 91—94,
96 —981. The severity of histopathologic lesions varies considerably
among studies. Although various classifications of liver disease
have been used, from my review, I believe that 0% to 79% of
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Table 3. Prevalence of cirrhosis in HCV-infected renal transplant
recipients
Authors
No. of
patients
Histologic diagnosis
of cirrhosis
Morales et al, 1993 [841
Roth ci at, 1994 [831
Chan et al, 1994 [921
Glicklich et al, 1994 [93)
Botetis et al, 1995 [91]
Hestin et a!, 1995 [851
Orloff et al, 1995 [941
Deladetsima et al, 1995 [961
Morales, 1995 [98]
Berthoux, 1995 [86]
Pouteil-Noble ci a!, 1995 [87]
27
10
13
29
37
30
8
68
30
59
81
5 (19%)
1(10%)
1(8%)
2 (7%)
2 (5%)
3 (10%)
0 (0%)
3 (4%)
7 (23%)
1(2%)
8 (10%)
a Numerals in brackets refer to reference numbers
HCV-infected renal transplant recipients could be classified as
having normal histology, non-significant, or mild lesions; 12% to
55% as having more severe lesions; and 0% to 23% as having
cirrhosis (Table 3) [83—87, 91—94, 96—981. The wide variation in
the severity of hepatic lesions could be attributed to the criteria
used for performance of liver biopsy. When liver biopsy is
performed regardless of the presence or absence of abnormal liver
function tests, in a substantial proportion of patients it reveals
normal histology, non-significant, or minimal changes [86, 91, 93,
96]. In contrast, when liver biopsies are performed only in patients
with liver functional abnormalities, more severe lesions predom-
inate [83, 84]. For example, in the studies by Morales et al [98] and
Roth et al [83], in which all patients who underwent liver biopsy
had long-standing biochemical evidence of chronic liver disease,
the prevalence of cirrhosis was 23% (7/30) and 20% (2/10),
respectively. On the other hand, in our study in which liver biopsy
was done irrespective of liver functional abnormalities, the prev-
alence of cirrhosis was only 4% (3/68) [96]. Another factor that
should be considered in the evaluation of the histologic data in
HCV-infected renal transplant recipients is the timing of the liver
biopsy. In all histopathologic studies, liver biopsy was performed
within a relatively short period after transplantation, between one
and 144 months (Table 4). Early biopsy could account for the
relatively high prevalence of mild histologic forms of liver disease
observed, as it is known that in patients with hepatitis C virus
infection, severe hepatic lesions such as cirrhosis can take as long
as 20 or 30 years to develop. This view is supported by the findings
of Hestin and coworkers, who noted that post-transplantation
time was significantly longer in 16 transplant recipients with a
Knodell index of greater than 5 (chronic hepatitis) than in 14
patients with a Knodell index of less than 5 (58 56 months
versus 35 29 months, P < 0.001) [85]. The relatively high
prevalence of cirrhosis reported by Morales et al possibly could be
explained by the fact that more than one-half of their patients had
biochemical evidence of chronic liver disease before transplanta-
lion [84, 98]. That is, the time interval between onset of liver
disease and liver biopsy might have been relatively long.
Another explanation for the wide variation in the severity of
hepatic lesions might be infection with different hepatitis C virus
genotypes [99]. For example, in the French and Italian general
population with hepatitis C, genotype lb/Il is the most prevalent
and is more frequently associated with cirrhosis than are other
genotypes [99]. Note that Patient 2, who developed severe liver
Table 4. Time interval between renal transplantation and performance
of liver biopsy in HCV-infected renal transplant recipients
Authors
Time from transplantation
until liver biopsy (months)
Mean SD Range (months)
Morales et at, 1993 [84]' 48 17 12—144
Roth ct al, 1994 [831 64.8 17 41—92
Chan et al, 1994 [92) 39.0 31.2 —
Glicklich et at, 1994 [93] — 1—232
Boletis ci al, 1995 [91]
Hestin et a!, 1995 [851
27 26 1—113
58 56 (KI > 5)h
35±29(KI<5) —
Orloff et at, 1995 [941 — 2—7 years
Deladetsima et al, 1995 [961 33.5 30.6 —
Morales, 1995 [98] 66 17 12—144
Berthoux, 1995 [861 43 3—96
Numerals in brackets refer to reference numbers
b KI, Knodell index
disease, was infected with this genotype (ib). Of our 68 patients,
only two liver biopsies (3%) revealed advanced fibrosing choles-
tatic hepatitis; in two other patients (3%), the biopsy specimen
revealed an early stage of this lesion [96]. These four patients had
the heaviest viral load compared with patients in the other
histologic groups, although the differences were not statistically
significant (unpublished data). To date, this aggressive form of
liver disease was thought to occur only from recurrent hepatitis B
in patients receiving liver grafts [100, 101]. Recently, however,
fibrosing cholestatic hepatitis has been described in two hepatitis
B virus-infected renal transplant recipients [102, 103] and in one
heart transplant recipient with donor organ-transmitted hepatitis
C virus infection [104].
Clinical and biochemical studies suggest that the course of
chronic liver disease in a substantial proportion of HCV-infected
renal transplant patients is not progressive. But histologic data,
which are more reliable, indicate that the course of liver disease is
characterized by progressive fibrosis. Liver disease progressively
worsened in 11 of 14 consecutive HCV-infected renal transplant
recipients (79%) who underwent liver biopsies within 24 to 144
months (development of cirrhosis in three and deterioration of
the Knodell index in eight) [84]. We recently studied the course of
liver disease in 15 HCV-infected renal transplant recipients whose
initial biopsy showed chronic hepatitis (13 patients), early fibros-
ing cholestatic hepatitis (one patient), or minimal hepatitis (one
patient) [96]. Followup biopsies were performed 17.1 4.9
months after the initial biopsy. Despite the short interval between
biopsies, the extent of fibrosis (stage) increased significantly in the
13 patients with chronic hepatitis (histologic index, 0.8 0.8
versus 1.6 0.9, P = 0.03), although these patients' necroinflam-
matory lesions (grade) remained virtually unchanged (histologic
index, 4.0 2.1 versus 3.3 1.7, P = 0.5). In the patient whose
initial biopsy showed early fibrosing cholestatic hepatitis, followup
biopsy disclosed evolution to the full-blown syndrome; in the
patient who was initially diagnosed as having minimal hepatitis,
followup biopsy revealed early fibrosing cholestatic hepatitis [96].
At present, no firm conclusions can be drawn regarding the
course of liver disease in HCV-infected renal transplant recipients
because: (1) the number of patients included in the histologic
studies is small, and (2) the time interval between initial and
subsequent biopsies is relatively short, and hepatitis C virus
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infection has a long natural history. Large, long-term, comparative
histopathologic studies, supplemented with detailed virologic
data, are needed to define precisely the course of liver disease in
hepatitis C virus-infected renal transplant recipients. Some data
indicate that the course of liver disease is more aggressive when
hepatitis C virus infection is acquired at the time of transplanta-
tion, rather than before or after [71].
The critical question, however, is not whether there is hepatic
disease, but whether hepatitis C virus infection alters patient
outcome. Several studies have shown that hepatitis C virus
infection does not affect survival of renal transplant recipients [39,
83, 84, 86, 88, 89, 94, 97, 98, 105, 106]. Recently, however, Pereira
and colleagues reported a significantly higher mortality rate (9/22,
41% versus 12/78, 15%; P = 0.009) and a 3.3-fold increased risk
of death after renal transplantation in patients who were anti-
HCV positive prior to transplantation, compared with patients
who were anti-HCV negative before transplantation [90]. The
causes of death also were significantly different (P = 0.02)
between the two groups. Sepsis was the major cause of death in
patients who were anti-HCV positive prior to transplantation;
these patients had a 9.9-fold increased risk of dying from sepsis
after transplantation [90]. This study contrasts with other investi-
gations, which have shown that anti-HCV neither affects patient
survival nor is associated with an increased incidence of death due
to sepsis or liver failure [39, 83, 84, 86, 88, 89, 94, 97, 98, 105, 106].
Pereira et al have proposed possible explanations for this discrep-
ancy: differences between the studies regarding the prevalence
and severity of the liver disease before transplantation, differences
in the virulence between strains of the virus, and differences in
"completeness" of the studies. These investigators posed the
critical question: should anti-HCV-positive dialysis patients un-
dergo transplantation or continue dialysis?
Apart from patient survival, the other major concern in renal
transplantation is graft survival. Pouteil-Noble et al found that the
incidence of acute rejection episodes was significantly higher in
anti-HCV-positive than in anti-HCV-negative renal transplant
recipients (33/78, 87% versus 101/136, 74%; P < 0.004) [105].
Similarly, Roth and coworkers found the percentage of RIBA-
positive patients who experienced acute rejection episodes to be
nearly twice that of RIBA-negative patients (40/109, 37% versus
41/200, 20%; P < 0.002) [83]. But several other studies have
shown no significant differences in the incidence of acute rejection
episodes between HCV-infected and non-infected renal trans-
plant recipients [88, 90, 94, 106]. In addition, recipients who were
anti-HCV positive prior to transplantation tended to have fewer
rejection episodes than did recipients who were anti-HCV nega-
tive prior to transplantation [90]. In search of an explanation for
the increased incidence of rejection episodes in their patients,
Roth and colleagues suggested two possibilities: (1) that the
causative factor was the markedly reduced amount of immuno-
suppressive therapy received by their patients following a serious
infection (42% of their RIBA-positive patients with infection had
at least one rejection episode), and (2) that, analogous to the
association of cytomegalovirus infection and rejection, hepatitis C
virus infection upregulates MHC class-Il antigens in the allograft
[83]. Corell et al observed a significantly lower incidence of acute
rejection episodes in anti-HCV-positive compared with anti-
HCV-negative renal transplant recipients (28% versus 40%; P
0.025), even though a significantly higher proportion of immuno-
logically high-risk patients belonged to the anti-HCV-positive
group (30.5% versus 11.8%; P = 0.00003) [107]. This lower
incidence was attributed to the relative reduction of CD4 CD5RA
(naïve T-helper) cells in anti-HCV-positive patients, a reduction
associated with altered T-cell proliferative responses to different
mitogens.
Chronic hepatitis C virus infection is associated not only with
hepatic lesions, but with a variety of immunologically mediated
extrahepatic conditions as well, particularly mixed cryoglobuline-
mia and glomerulonephritis (GN) [108]. Hepatitis C virus is the
major cause of essential mixed cryoglobulinemia; anti-HCV and
HCV RNA are detectable in the serum of more than 80% of
patients with this condition [108]. Although membranoprolifera-
tive glomerulonephritis (MPGN) is the most common form of GN
observed in HCV-infected patients, other forms such as membra-
nous, acute proliferative, and sclerosing ON have been reported
[109]. Does de-novo HCV-related GN develop in HCV-infected
renal allograft recipients? Epidemiologic data indicate such a
possibility. Membranous nephropathy occurred more frequently
in anti-HCV-positive than in anti-HCV-negative renal transplant
recipients (6/141, 4% versus 2/455, 0.44%; P < 0.02) [110].
Berthoux's review of all graft biopsies performed on 399 renal
transplant recipients revealed 12 cases of membranous GN and 9
cases of MPGN [86]. The prevalence of hepatitis C virus infection
was 25% (3/12) in patients with membranous ON and 78% (7/9)
in patients with MPGN. Compared to the prevalence of HCV
infection in the entire renal transplant group (117/399, 29%), the
prevalence of HCV infection was significantly different only for
MPGN (P = 0.001). Moreover, a ninefold increase in the preva-
lence of MPGN was observed among HCV-infected, compared
with non-HCV-infected, recipients (7/117, 6% versus 2/282,
0.7%). Recent non-epidemiologic data support the potential
association between HCV infection and MPGN in renal trans-
plant recipients. Roth and colleagues described five HCV-infected
noncryoglobulinemic renal transplant recipients with proteinuria
due to MPGN; in none of these patients was MPGN or a known
immune-complex disease the cause of the original nephropathy
[111]. Comparison of the physicochemical properties of the HCV
virions between these patients and five HCV-infected, non-
proteinurie renal transplant patients provided indirect evidence
that immune complexes consisting of HCV antigen and anti-HCV
antibody are present in the circulation of HCV-infected recipients
with MPGN.
Hepatocellular carcinoma (HCC), another serious complica-
tion of HCV infection, is observed more frequently in some parts
of the world. In Japan, for example, where HCC is one of the most
common forms of cancer, mortality rates show a constant and
significant increase [112]. In the general (worldwide) population,
HCC occurs more frequently in patients with chronic hepatitis C
than in patients with chronic hepatitis B, and HCC can develop in
non-cirrhotic patients with chronic hepatitis C [113, 114]. Data
regarding the development of HCC in HCV-infected renal trans-
plant recipients are lacking, probably because of the short fol-
lowup period of the studies; it is known that HCC is a late
complication of HCV infection. Noteworthy is that non-Hodgkins'
lymphoma recently was diagnosed in 14 non-transplant patients
with chronic hepatitis C [115]. In all 14, anti-HCV and HCV RNA
were present in the serum, and HCV RNA was present in
peripheral blood mononuclear cells.
Some data have become available regarding patients who are
co-infected with the hepatitis B and hepatitis C viruses. Huang et
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a! compared 28 anti-HCV-positive/HBsAg-positive and 51 anti-
HCV-positive/HBsAg-negative renal transplant recipients [1161.
No differences appeared in the prevalence of deaths related to
liver disease, but chronic hepatitis and cirrhosis occurred more
frequently in the co-infected patients than in patients who were
anti-HCV positive only (50% versus 25.5%; P = 0.026 for chronic
hepatitis, and 21% versus 0%; P = 0.001 for cirrhosis). Recently,
Pouteil-Noble and colleagues studied 235 renal transplant recip-
ients, of whom 189 were HCV infected and 46 were co-infected
with the HCV and HBV at the time of transplantation [87].
Following transplantation, biochemical evidence of chronic hep-
atitis was present in 50% of the HCV-infected and in 64% of the
co-infected recipients. Although patient survival did not differ
between the two groups, hepatic failure was observed more
frequently among the HCV/HBV co-infected patients (7/41, 17%
versus 12/156, 7%). Furthermore, liver biopsy in 108 patients (81
HCV infected and 27 HCV/HBV co-infected) showed that the
incidence of minimal-change lesions was higher in HCV-infected
(13/81, 16%) than in HCV/HBV co-infected (2/27, 7.5%) patients
[871. In contrast, the incidence of cirrhosis was higher in HCV/
HBV co-infected patients (7/27, 26%) than in patients who were
infected only with hepatitis C(8/81, 10%) [87]. These data suggest
that, in HCV-infected renal transplant recipients, co-infection
with HBV is associated with more aggressive liver disease.
How should we manage the renal transplant recipient with
HCV infection? We have some information about two possible
approaches: reduction of immunosuppression and treatment with
interferon alpha (INF-a). Hepatitis C virus RNA titers rise after
transplantation in HCV-infected renal transplant recipients. An
association between immunosuppression and number of serum
HCV RNA titers also has been found [117]. Therefore, reduction
of immunosuppression might benefit the patient by decreasing the
degree of viremia. Reducing immunosuppression should be con-
sidered carefully, however, because this approach has been re-
lated to acute rejection [83]. Nevertheless, since there are no firm
data regarding the harmfulness of specific immunosuppressive
drugs, we tend to concentrate on the net state of the patient's
immunosuppression. Therefore, in our department, all the HCV-
infected renal transplant recipients receive reduced doses of
immunosuppressive drugs without exclusion of any specific drug.
Interferon alpha, apart from having antiviral properties, is
immunostimulatory as well. It can increase the expression of HLA
antigens by the cells, induce cytokine gene expression, and
enhance the effector function of cytotoxic T-lymphocytes, natural
killer cells, and macrophages [71, 118—1201. These properties
might explain the high incidence of acute, irreversible vascular
rejection observed approximately 10 years ago in renal transplant
recipients receiving INF-a prophylactically for cytomegalovirus
infection [121, 122]. Thervet et al conducted a pilot study in which
13 renal transplant recipients with biopsy proven chronic hepatitis
received r-INF-a for a mean of 4.5 (one to 11) months [123].
Clinical tolerance was poor (treatment had to be withdrawn in
more than one-half of the patients) and, although liver enzyme
activities were reduced during treatment, they returned to pre-
treatment levels after therapy ended. Furthermore, 2 of 12
patients developed acute deterioration of graft function. Rostaing
and colleagues prospectively studied 16 renal transplant recipients
with chronic hepatitis C and stable renal function for at least one
year (serum creatinine, 1.4 0.5 mg/dl), who were scheduled to
receive r-INF-a (3 MU 3 times/week for 6 months) [124]. Fifteen
of the patients were HCV RNA positive at the beginning of the
study. During treatment, ALT levels returned to normal in 15 of
the patients (94%), but 7 of the responders (47%) relapsed one to
9 weeks after discontinuation of treatment. One month after
treatment, HCV RNA was present in the serum of all patients
who were viremic before therapy started. In this study as well,
tolerance to the drug was poor; 4 patients (25%) dropped out of
the study because of side effects. A worrying finding in this study
was the significant increase in serum creatinine levels observed
during INF-a treatment (162.5 57.6 versus 125.4 41 jtmol/
liter; P < 0.05), with renal failure developing in 6 of the patients
(38%). Two of these six responded to methylprednisolone antire-
jection treatment with improved graft function; renal failure
progressed in the remaining four. Graft biopsy in patients with
deterioration of renal function during INF-a treatment revealed
various lesions, including acute tubular necrosis with interstitial
hemorrhage in one patient, chronic rejection in another, and
interstitial edema with scattered mononuclear cell infiltration and
mesangial hypertrophy in others [123, 124]. None of the patients
had the lesions of acute cellular or vascular rejection that had
been described in earlier studies [121, 122]. It is therefore possible
that INF-a causes deterioration of graft function in renal trans-
plant recipients not only by inducing acute rejection but also
through other mechanisms. Such mechanisms could include direct
nephrotoxicity, induction of cytokines, and acute interstitial ne-
phritis [123, 124]. Current data thus suggest that INF-a therapy
can be potentially dangerous in HCV-infected renal transplant
recipients.
Reduction of immunosuppression is a possible, albeit a seri-
ously flawed, approach to therapy in the HCV-infected renal
transplant recipient. But I believe that using interferon alpha is
untenable given the current evidence. I agree with Thervet et a!:
"The use of INF-cs is likely to be avoided in this specific
indication" [123], and with Rostaing and colleagues: "We do not
recommend using INF-n for chronic hepatitis C in renal trans-
plant recipients" [124]. In our unit we are very reluctant to treat
HCV-infected renal transplant recipients with INF-cs. Perhaps
other, newer antiviral agents such as ribavirin will prove safer. To
the best of my knowledge, there are no published data regarding
the use of these agents in renal transplant recipients. So the
answer to the question of what can be done therapeutically for
renal transplant recipients with HCV infection is, very little if
anything at all.
Can anything be done to help these patients while they are
undergoing dialysis and awaiting transplantation? I don't know.
Recent clinical and clinicopathologic studies have shown that in
HCV-infected hemodialysis patients, INF-a treatment is well
tolerated and its efficacy is comparable to that observed in the
general population [125—1 27], but reappearance of viremia occurs
frequently [127]. Pol et a! noted a discrepancy among biochemical,
histologic, and virologic parameters in a study of 19 HCV-infected
hemodialysis patients who underwent treatment with r-INF-a (3
MU three times/week for 6 months) [127]. Of the 12 patients
(75%) who underwent liver biopsy before and after treatment, 9
showed improvement or normalization of the hepatic lesions. Of
13 patients with abnormal liver tests, 11(85%) responded with
normalization of the tests, and 73% of the responders (8/fl) were
long-term responders. However, of 15 patients who were HCV-
RNA positive prior to treatment, 7 (47%) were HCV-RNA
positive at the end of treatment, and 12 (80%) were HCV-RNA
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positive at the end of the followup period [127]. Let me repeat:
frequent reappearance of viremia after INF-a treatment is a
serious problem. This especially applies to patients undergoing
lNF- treatment while they are renal transplant candidates,
because when the time for transplantation and initiation of
immunosuppressive therapy arrives, the majority of these patients
will still be viremic. Perhaps HCV-infected dialysis patients
require more prolonged treatment with INF-a. Poynard et al
recently suggested just that for patients with NANB hepatitis
[1281. Factors that one should consider in assessing the potential
response to INF-cs are quantity of viremia and hepatitis C virus
genotypes. Furthermore, neutralizing and binding interferon an-
tibodies were detected in the serum of HCV-infected patients
who, despite having an initial response, experienced relapse
during treatment with recombinant INF-n (breakthrough) [129].
In light of all these data, we should not draw definite conclusions
regarding the efficacy and safety of INF-a therapy in HCV-
infected dialysis patients until the results of large, prospective
controlled studies comparing different INF-a treatment regimens
are available. These studies will have to include detailed analyses
of the clinical, histologic, virologic, and immunologic parameters
of the patients before and after treatment.
Conclusions
I would like to conclude by highlighting the significant issues
relating to hepatitis C infection in renal transplant recipients. (1)
Most HCV-infected renal transplant recipients acquire the infec-
tion during the pre-transplantation dialysis period. (2) Because
our knowledge of the factors responsible for HCV transmission in
the dialysis setting is incomplete, we do not yet have effective
measures for eliminating HCV transmission in the dialysis patient
population. (3) Hepatitis C virus infection is transmitted by organ
transplantation, but the incidence of transmission varies among
centers. (4) The majority of anti-HC V-positive donors are viremic
and, apparently, there are no low-risk, anti-HCV-positive donors.
(5) Transplantation of kidneys from anti-HCV-positive donors
into anti-HCV-positive recipients may be safe, but only in the
short term. Long-term studies including detailed virologic data
are needed to verify the safety of such transplantations. (6)
Hepatitis C-infected patients' livers are prone to a wide spectrum
of histopathologic lesions. Because no correlation exists between
liver histology and anti-HCV positivity, liver function tests, vire-
mia, or levels of viremia, liver biopsy is essential for diagnostic,
prognostic, and possibly therapeutic purposes. The histologic
course of liver disease seems to be that of progressive fibrosis.
Hepatitis C virus infection does not seem to affect graft survival.
The same applied for patient survival, but increased mortality
rates and increased risk of death have been noted recently.
Higher, unaffected, and lower frequencies of acute rejection
episodes all have been reported. De-novo HCV-related glomer-
ulonephritis, especially the membranoproliferative form, can oc-
cur. Therapy with TNF-a bears the risk of inducing acute rejec-
tion; INF-n therapy in patients awaiting transplantation needs
further evaluation.
In November 1989, Dr. Miriam J. Alter and Dr. Richard E.
Sampliner wrote an editorial in the New England Journal of
Medicine titled, "Hepatitis C and miles to go before we sleep"
[1301. This title was inspired by the poem "Stopping by Woods on
a Snowy Evening," by the famous American poet Robert Frost.
The poem concludes:
The woods are lovely, dark and deep,
But I have promises to keep,
And miles to go before I sleep,
And miles to go before I sleep.
The title of that editorial still applies today. But an ancient
Chinese proverb says that before one can reach a destination one
thousand miles away, one must take the first step. I think we have
taken that first step with hepatitis C, and I feel certain that soon
the thousand-mile destination will be reached.
QUESTIONS AND ANSWERS
DR. NlcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): You referred to
rapid-sequence variation of the hype rvariable region of HCV and
formation of escape variants. Does the rate of formation of such
variants increase with INF-a or immunosuppressive therapy?
DR. V0sNIDEs: The limited data on this issue are based on a
small number of patients. In a study from England, sequence
nucleotide changes of the hypervariable region located in the
E2/NSI protein of the HCV genome occurred more commonly in
two untreated than in two IFN-a-treated patients with chronic
hepatitis C [131]. In a Japanese study, multiple sequence varia-
tions of the hypervariable part of the E2/NS1 region were
frequent in three patients with chronic hepatitis C who did not
respond to INF-p therapy, but the variations were not observed in
three responders [132]. In a more recent French study of patients
with serologic evidence of active HCV infection receiving INF-13
therapy, the nucleotide sequence variation of the El region of the
HCV genome was low, regardless of the response to treatment
[133]. In contrast, an increased degree of sequence variation was
observed in the E2 region of the HCV genome of patients
undergoing INF therapy.
Regarding the effect of immunosuppression, I am aware of few
data. An agammaglobulinemic HCV-infected patient was re-
ported, in whom the nucleotide sequence of the hypervariable
region in the envelope glycoprotein (E2/NSI) remained un-
changed over a period of 2.5 years [1341. Recently, the distribution
of nucleotide sequences from the 5' UT region and from a
fragment of the E2/NS2 region of the HCV genome was deter-
mined before and after transplantation in two HCV-infected liver
transplant recipients. In both patients, although the consensus
nucleotide and amino acid sequences remained unchanged, the
complexity of the viral quasispecies decreased after transplanta-
tion [1351. In a study presented at the 1995 EDTA Congress, HCV
genotypes remained constant over a period of 2 to 7 years after
transplantation in six renal transplant recipients with chronic
hepatitis C [136]. However, this abstract did not mention whether
the nucleotide sequence variation of the hypervariable regions of
the HCV genome was analyzed.
DR. MADIAs: Are there cases of double infection with HCV of
different types?
DR. V05NIDEs: Mixed infections with different HCV genotypes
have been documented in patients with chronic hepatitis C from
the general population [9, 137] as well as in hemophiliacs [138].
The prevalence of mixed infections with HCV of different types
also is higher among patients who have acute exacerbations of
chronic hepatitis C than among those who do not [137]. Mixed
infections with HCV of different genotypes also occur in hemo-
dialysis patients [125] and in renal transplant recipients [136, 139].
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DR. MADIAs: Are data available on comparable anti-HCV-
positive patients who were either maintained on hemodialysis or
who received transplants that will allow us to judge the impact of
transplantation on the natural course of HCV-associated hepatic
disease?
DR. V05NIDE5: I am not aware of any controlled studies
comparing the course of liver disease in HCV-infected dialysis
patients with that of HCV-infected renal transplant recipients.
Perhaps Dr. Levey would be willing to comment on this.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): Dr. Pereira and I and our colleagues recently
have concluded a large study to assess the impact of HCV
infection and mode of renal replacement therapy on survival in
patients who had been referred to the New England Organ Bank
for renal transplantation [401. During a median followup of six
years, approximately 60% of patients received a transplant and
30% died. Controlling for a number of baseline factors, we found
that patients with anti-HCV at the time of referral had a higher
risk of death. The higher relative risk of death in the anti-HCV-
positive patients did not differ significantly among patients who
received a transplant or those who remained on dialysis. These
findings suggest that HCV infection adversely affects survival in
end-stage renal disease irrespective of mode of therapy, but that
transplantation does not adversely affect survival rates in patients
with HCV infection. Although this study does not substitute for a
randomized controlled trial, we think it is the best information we
can present so far. We conclude that anti-HCV-positive status
alone is not a contraindication for renal transplantation. We
recommend that anti-HCV-positive patients with end-stage renal
disease be allowed to make an informed choice between dialysis
and transplantation.
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts): You mentioned that Zucker
and associates reduced the hepatitis C transmission to zero when
they utilized a filter in their pulsatile perfusion system [66]. Are
you using such a system? Should we all be using such a system?
DR. VOSNIDES: No, we use slush preservation. But it is possible
that the size of the viral inoculum plays an important role in the
transmission of HCV infection and the induction of HCV-related
liver disease. Zucker et al used refined molecular biology tech-
niques and found that (1) the kidney is not a site of HCV
replication, and (2) modifications of the standard pulsatile perfu-
sion technique completely eliminated the virus from the HCV-
infected kidneys [661. It is thus possible that with these preserva-
tion techniques, the viral burden of the procured kidneys from
HCV-infected donors, and consequently the viral inoculum, is
reduced or completely eliminated, and that the risk of transmis-
sion of HCV decreases significantly or even possibly disappears. If
future studies prove that the technique reported by Zucker et al
eliminates the risk of transmission of HCV from infected donor
kidneys, then yes, I think all of us should be using such a
preservation system.
DR. MADIAS: How would you manage the anti-HCV patient on
hemodialysis who wishes to receive a renal transplant?
DR. VosNmEs: This is a one million dollar—or 247 million
drachmas—question. Our decisions rely mostly on liver histopa-
thology and the presence of viremia. As a general rule, we do not
offer transplants to patients with high degrees of necroinflamma-
tory activity or fibrosis on liver biopsy. Our current policy could be
summarized as follows: Serum HCV RNA is determined in all
anti-HCV-positive dialysis patients regardless of liver function
tests; the same applies for all anti-HCV-negative patients with
persistently abnormal liver function tests. All anti-HCV-positive
and/or HCV-RNA-positive patients undergo liver biopsy. With
the exception of patients whose liver biopsy shows advanced
cirrhosis, all viremic patients receive treatment with INF-a, 3
million units 3 times weekly for one year. In fact, we are
contemplating extension of the treatment to 18 months, and we
also are considering the possibility of treating our patients with a
combination of INF-a and ribavirin. If the initial biopsy shows
mild lesions (low grade and low stage), we probably would avoid
performing a second liver biopsy. Otherwise, a second liver biopsy
is performed when the INF-s therapy is completed. If significant
improvement or normalization of the histologic lesions is seen on
the second biopsy specimen, and the patient becomes free of
viremia, renal transplantation is offered, although ideally we
should wait another six months and determine whether the patient
remains free of viremia. I must admit that we have transplanted
kidneys into a limited number of patients who have had mild
hepatic lesions, even if they were viremic. Yet we are puzzled
about whether we are doing the right thing. In some of these
patients, post-transplantation followup liver biopsies showed no
significant changes compared to the initial biopsy, while in other
patients, the extent of fibrosis increased significantly. Neverthe-
less, the necroinfiammatory lesions remained the same or even
decreased slightly. I know that our policy sounds strict. However,
we have seen quite a few renal transplant recipients with HCV-
related hepatic disease that caused considerable morbidity, in
some cases, cirrhosis and even death from liver failure usually
associated with infection. Another factor that strongly affects our
decisions is the serious shortage of donor organs in Greece. We
do a lot of living-related renal transplantations. As a matter of
fact, last year more than 50% of renal transplantations performed
in this country were from living-related donors. In the setting of
transplantation from living donors, you have to make the best of
it, and preparation of the recipient should be meticulous, even
"ideal."
In their recent study from the New England Organ Bank,
Pereira et al demonstrated that pre-transplantation HCV infec-
tion is associated with an increased risk of liver disease and death
after transplantation [901. These results made us skeptical of
whether anti-HCV-positive patients on dialysis should be offered
renal transplantation as opposed to continuing dialysis. We are
currently trying to find out whether a relationship between the
severity of the initial liver histopathologic lesions, histopathologic
course of liver disease, and HCV genotypes exists. This informa-
tion probably will give us some guidelines as to whether in some
patients, for example those infected with the genotype ib, a strict
transplantation policy should be applied, whereas in other pa-
tients, for example those infected with genotype 2 or 3, a more
liberal policy could be adopted.
DR. MADIAS: Dr. Levey, could you describe to us your views on
this issue?
DR. LEVEY: 1 agree that patients with anti-HCV and evidence of
liver disease (persistently or intermittently elevated serum
transaminase level) should have a liver biopsy prior to renal
transplantation. Liver biopsy is the best method for assessing the
prognosis of liver disease after transplantation. This information
is important, because if the biopsy reveals an advanced degree of
liver damage, either according to the necrosis index or the fibrosis,
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the outcome after renal transplantation is likely to be poor, and I
think it is very important that the patient knows that. It is also true
that the outcome of dialysis also is likely to be poor, and the
patient deserves to know this as well. I am intrigued by the idea of
treating these patients with interferon prior to transplantation,
but until the long-term results of this approach are known, I am
not ready to make as sweeping a recommendation as you have. As
you know, most patients with anti-HCV do indeed have viremia.
Based on the response of non-immunosuppressed patients to
interferon therapy, I suspect that the number of patients who
would be rendered free of viremia is probably relatively small, and
immunosuppression might reactivate HCV infection. So I differ
with you, Gregory, on this: I wouldn't prohibit anti-HCV-positive
patients from making their own choice whether to have a renal
transplant if the biopsy showed only mild liver disease. We don't
have studies demonstrating that their long-term prognosis is
worse than if they did not receive a transplant. In fact, our recent
study suggests that we can't tell them that the prognosis is worse
[1401. Although I am concerned that it might he worse, my own
concern should not prevent them from having a renal transplant if
their quality of life on dialysis is poor.
DR. VosNiDes: You recently found that viremia increases
tremendously after transplantation and initiation of immunosup-
pression [88]. You found that the median increase in post-
transplantation HCV RNA titer was 6.6-fold and that the increase
ranged from 1.8- to 30.3-fold.
DR. LEVEY: Yes, these patients are at risk for viremia, but our
study suggests that the increase in risk of death is not significantly
different whether they remain on dialysis or receive a transplant.
DR. DEMETRIOS VLAHAKOS (Onassis Cardiac Surgery Center,
Athens): You mentioned that hepatitis C does not adversely affect
graft survival and that death from hepatic complications in
HCV-infected patients occurs in the late post-transplant period,
years after transplantation. Since transplantation is a cost-effec-
tive method that offers the best quality of life in patients with
end-stage renal disease, could we not transplant organs from
HCV-positive donors to recipients with co-morbid conditions who
are expected to live less than two or three years on hemodialysis?
DR. V0SNwES: I am not aware of any formal studies addressing
this issue. Organs (heart, liver, and lung) from HCV-infected
donors have been used for life-saving transplants. I should clarify
that all the data I cited refer to the course and outcome of hepatic
disease in HCV-infected dialysis patients undergoing renal trans-
plantation. Regarding the dialysis patients who acquire HCV
infection at the time of transplantation, for example, by receiving
a kidney from an HCV-infected donor, the course of the liver
disease is probably different. Some evidence suggests that the
course of liver disease in such patients is more aggressive than in
those who acquire the infection prior to transplantation, while
they are on dialysis [69, 86, 1041. We have had the same
experience, albeit in a small number of patients. Perhaps hepatic
disease is more virulent in renal transplant recipients who acquire
HCV infection at the time of transplantation because they
develop acute hepatitis while receiving maximum immunosup-
pression. So, although your suggestion is not unreasonable, I am
worried that by adopting such a policy, another morbid condition,
that is, liver disease, will he added to patients who already have
other serious co-morbid conditions and, therefore, death could
occur sooner than expected had they not acquired HCV infection.
DR. VLAHAK0S: The ELISA-2 can recognize more epitopes on
the HCV antigen and thus is a more sensitive test. Does this imply
that the ELISA-2 is less specific?
DR. V05NIDEs: The ELISA-2 test for detecting anti-HCV
antibody is both more sensitive and more specific than the
ELISA-1 test [10, 15, 16]. The sensitivity and specificity of
ELISA-2, evaluated in the serum of hospitalized patients and
healthy adults using HCV RNA detection by PCR as an indicator
of active infection, was 93.9% to 100% and 97.9% to 100%,
respectively [141].
DR. DEMETRIOS STAMATIADES (Division of Nephrology, Laiko
General Hospita4 Athens): Do you have any data regarding other
types of liver disease apart from cirrhosis and mild hepatie
disease? For example, what is the prevalence of chronic active
hepatitis in anti-HCV-positive renal transplant recipients?
DR. V0sNIDE5: I am glad you asked that question. When I was
preparing this presentation, I tried to construct a table showing
the reported prevalence of the various histologic forms of chronic
hepatitis C in renal transplant recipients. But I found it impossi-
ble, because different studies use different classifications. In some
studies, the conventional classification of chronic hepatitis—
lobular, chronic persistent, and chronic active—is used, other
studies use the Knodell index, and yet others adopt newer
classifications. For example, our own pathologist now uses the
recent classification proposed by Ishak et al only about a year ago
[1]. 1 found it impossible to construct a table with a homogeneous
classification of the various histopathologic lesions of chronic
hepatitis C observed in renal transplant recipients. I can say this:
in the studies using the conventional histologic classification of
chronic hepatitis, the prevalence of chronic active hepatitis in
I-ICV-infected recipients was 12% to 50% [81, 82, 85, 92, 103,
104].
DR. CHRIsros IATROU (Division of Nephrology, Athens General
F-Iospita4 Athens): Has anything been reported regarding the
presence of hepatitis C virus in the liver of renal transplant
recipients with hepatitis C viremia?
DR. VOsNIDE5: Hepatitis C virus RNA has been detected in the
livers of HCV-infected non-transplant patients via various tech-
niques (immunohistochemical staining, in-situ hybridization, and
in-situ PCR) [142]. Furthermore, the bDNA technique has dis-
closed a significant correlation between serum and liver viral load
[143]. Using RT-PCR, a recent French study detected HCV RNA
in the livers of 29 of 30 (97%) renal transplant recipients with
detectable HCV RNA in the serum [83].
DR. MADIAs: Is any information available about treating HCV
infection with INF-f3?
DR. V05NIDE5: I am aware of three studies, all from Japan
[144—146]. In the first study, a prospective controlled trial includ-
ing 25 patients with acute non-A, non-B hepatitis, 11 of the
patients were treated with INF- for an average of 30 days, and 14
acted as controls (no treatment) [144]. Four patients in the
treatment group still had raised ALT levels after one year
followup and therefore were given a second course of INF-13.
Followup at three years revealed that 10 of the ii treated patients,
but only 3 of the 14 controls, had normal serum ALT levels.
Serum HCV RNA was undetectable in 10 of the 11 treated
patients and in only 1 of the 12 controls. In the second study,
INF-p was given to 97 consecutive patients with acute non-A,
non-B hepatitis who were randomly allocated to six different dose
regimens [145]. The total dose of INF-p ranged between 8.4
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million and 336 million units. Seventy-four patients were anti-
HCV positive (ELISA-2); of these, 65 were HCV-RNA positive.
Ninety patients (74 with hepatitis C and 16 with non-hepatitis C)
were analyzed at the end of the trial. Biochemical resolution, that
is, normalization of the ALT level, was observed in 15 of the 16
(94%) patients with non-hepatitis C (anti-HCV negative/HCV-
RNA negative). In contrast, only 28 of 74 (38%) anti-HCV-
positive patients showed biochemical resolution. Then the rate of
biochemical resolution was determined in the six different treat-
ment groups. Among anti-HCV-positive patients, only the pa-
tients who received the highest total dose (336 million units)
showed a high resolution rate (10 of 12, 83%); in the other five
groups (lower total dose of INF), the resolution rate ranged
between 0% and 38%. Similarly, among the 65 HCV-RNA-
positive patients, sustained disappearance of viremia was ob-
served in 90% (9 of 10) of those receiving the highest dose (total
dose, 336 million units) and in 0% to 46% of the patients receiving
the lower dose (total dose, 8.4 million to 168 million units). Also,
biochemical resolution of acute hepatitis C was accomplished
even in patients with high levels of viremia, provided sufficiently
large doses of INF-/3 were given. The third study, using detection,
typing, and quantification of serum HCV, comprised 50 randomly
selected patients with chronic hepatitis C [146]. Of the 50, 24
responded to INF-f3 therapy with sustained normalization of ALT
(complete responders), and 26 did not respond (nonresponders).
The pretreatment levels of viremia were significantly lower in
complete responders than in nonresponders, whereas genotypes
did not seem to influence the response to INF-13 therapy.
DR. VALSAMAKIS HADJICONSTANTINOU (Chief Division of Ne-
phroloy, Amalia Fleming Hospital, Athens): Are you aware of any
study comparing the outcome of renal transplantation between
hepatitis-B-infected and hepatitis-C-infected renal transplant re-
cipients?
DR. VOSNIDES: Let me refer your question to Dr. Boletis, who
presented our data at the Congress of the European Society for
Organ Transplantation (ESOT) in Vienna.
DR. JOHN BOLETIS (Division of Nephrology, Laiko General
Hospital): I am not aware of any study directly comparing the
outcome of hepatitis-B- and hepatitis-C-infected renal transplant
recipients. However, since the clinical and biochemical data do
not reflect the severity or the course of liver disease in these
immunosuppressed patients, we performed a total of 87 pre- and
post-transplant sequential percutaneous liver biopsies in 11
HBsAg(+)/anti-HCV(—) and 28 HBsAg(—)/anti-HCV(+) renal
transplant recipients and compared the histologic course. Our
findings suggest that hepatitis B has a more aggressive histologic
course than hepatitis C, and that this course coincides with the
post-transplantation reactivation of hepatitis B virus replication
[147].
DR. VOSNIDES: Our pathologist, Dr. Deladetsima, is here.
Perhaps she can comment on the histopathologic data and the
question asked by Dr. Stamatiades, because she is the one who
confuses us all the time!
DR. ANNY DELADETSIMA (Division of Histopathology, Laiko
General Hospital): We use the new classification of chronic
hepatitis for the interpretation of liver biopsies [1]. The new
classification, which has been widely accepted by hepatologists
internationally, is based on two parameters: (1) hepatitis activity
or grade, defined by the necroinflammatory changes such as
piecemeal necrosis, portal inflammation, and focal or confluent
necrosis of the parenchyma, and (2) stage of the disease, defined
by the extent of fibrosis. The stage is actually the result of the
activity and is related to the time course of hepatitis. The
peculiarity in our group of patients is the low hepatitis activity
compared to that of hepatitis C in the general population. In
addition, our patients develop fibrosis in a rather short time.
Higher-stage fibrosis develops in our patients in about two years,
but in the general population, the time interval for disease
progression is approximately nine years. Although stage increases
significantly, grade slightly decreases. A similar observation has
been made in liver transplant patients. In this group of immuno-
suppressed patients, histologic changes are more severe in the
early post-transplant period [148]. One can assume that the
improvement of histology in later stages accounts for disease
activity and not for hepatitis stage.
DR. MADIAS: Dr. Deladetsima, membranoproliferative glomer-
ulonephritis, a relatively common entity in the U.S. in the 1970s
and early 1980s, is now rarely seen, likely because of HCV
screening of the blood supply [149]. Have you observed a similar
decrease in this region?
DR. DELADETSIMA: I see only liver biopsies and am not familiar
with renal histopathology.
DR. V0sNIDEs: Nor do I have data for this region. I do know
that in France, although the incidence of idiopathic membrano-
proliferative glomerulonephritis is declining [150], HCV infection
is common.
DR. BOLETIS: A 1993 French study found no relationship
between HCV infection and membranoproliferative glomerulo-
nephritis [151]. Nor did the Italian multicenter study [152, 153]. In
only one American [154] and one Japanese [155] study was a
relationship between HCV infection and membranoproliferative
glomerulonephritis found. I think this issue is controversial.
DR. HADJICONSTANTJNOU: I would like to return to the question
of the current incidence of hepatitis C in the so-called developed
world, including the hemodialysis population. It appears that
hepatitis B continues to be a major problem in hemodialysis units,
even in the Western world. We would expect that the situation is
improving, owing to the testing of blood and blood products
before transfusion, a substantial decrease in the need for blood
transfusions in the erythropoietin era, and the widespread vacci-
nation of all hemodialysis patients against hepatitis B. However, I
was surprised by a communication in the U.S. Centers for Disease
Control's Morbidity and Mortality Weekly Report about outbreaks
of hepatitis B among hemodialysis patients in California, Ne-
braska, and Texas in 1994 [156]. Amazingly, most of the patients
had not been vaccinated against hepatitis B, although the vaccine
has been commercially available for the past 15 years. So what can
we expect for hepatitis C, for which no vaccine is yet available?
DR. LEVEY: Hepatitis B vaccine is sometimes not used routinely
in hemodialysis patients in the U.S. because the prevalence of
HBV infection in this group is low, the efficacy of the vaccine in
stimulating antibody production is not high, and other infection
control measures generally are sufficient to prevent the spread of
infection. However, in hemodialysis populations with a high
prevalence of HCV infection, HCV appears to be transmitted in
the dialysis unit [157], and I suspect an effective vaccination would
be widely used.
DR. CHARALAMBOS STATHAKIS (Division of Nephrology, Laiko
General Hospital): Do any factors influence the response to
treatment with INF-a in patients with chronic hepatitis C?
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DR. VosNIDEs: Several reports have indicated the presence (or
absence) of certain factors associated with a favorable response to
INF-s therapy. These factors include, but are not restricted to,
female gender, young age, low body weight, history of intravenous
drug abuse, short duration of the disease, histologic evidence of
mild chronic hepatitis (chronic persistent or lobular hepatitis),
absence of cirrhosis, low serum HCV-RNA levels, infection with
genotype 2 or 3, absence of iron overload, low serum ferritin
levels, and low AST, yGGT, and bilirubin levels [see Ref. 1581.
Researchers at the Hospital for Infectious Diseases in Athens
found that the absence of the serum 1gM anti-HCV core antibody
is associated with a favorable response to INF-a therapy [1591.
DR. STATHAKIS: Does duration of treatment influence this
reponse?
DR. V0sNIDEs: In a French multicenter study, 329 patients with
chronic non-A, non-B hepatitis (of whom 252 were anti-HCV
positive) were treated for six months with 3 million units of INF-a
given subcutanously 3 times/week [126]. Subsequently, 303 pa-
tients were randomly allocated to receive the same treatment for
an additional 12 months (group 1, 103 patients), a regimen of one
million units three times/week for 12 months (group 2, 101
patients), or no further treatment (group 3, 99 patients). At 18
months, a significantly higher proportion of patients in group 1
(45%) had normal serum ALT values as compared with those in
group 2 (27%) and group 3 (30%). Similarily, between 19 and 42
months, a significantly higher proportion of patients in group 1
(22%) continued to have normal serum ALT as compared with
those in group 2 (10%) and group 3 (8%). Furthermore, among
176 patients with repeated liver biopsies at 18 months, signifi-
cantly more patients in group 1 (70%) had improved histologic
activity scores than in group 2 (48%) or group 3 (39%). So it
seems that for patients with chronic non-A, non-B hepatitis, a
regimen of 3 million units of TNF-a given 3 times/week for 18
months is more beneficial than lower doses or a shorter duration
of treatment.
DR. HARRINGTON: In renal transplant recipients, do liver biopsy
results correlate better with death from liver disease than do liver
function tests?
DR. V0sNIDEs: Renal transplant recipients with liver disease
due to various causes, not specifically HCV infection, have been
studied. Rao et al investigated liver biopsy results in 72 renal
transplant recipients with liver disease due to various potential
causes (mainly HBV infection, CMV infection, and alcohol abuse)
[74]. The histologic findings included fat metamorphosis (8 pa-
tients), chronic persistent hepatitis (20 patients), early chronic
active hepatitis (20 patients), advanced chronic active hepatitis
(15 patients), and hemosiderosis (9 patients). During a mean
followup of 5.7 3.9 years, progression to hepatic failure and
death occurred in 35% of the patients with early chronic active
hepatitis, 55% of the patients with hemosiderosis, and 60% of
those with advanced chronic hepatitis. None of the patients with
fat metamorphosis or chronic persistent hepatitis died of liver
failure. I am not aware of a similar study in renal transplant
recipients with liver disease due to hepatitis C. In most studies of
hepatitis C in renal transplant recipients, including the most
recent one from the New England Medical Center [90], liver
disease is defined by biochemical criteria. I know of no study
correlating liver histopathology with death from liver failure in
renal transplant recipients with HCV infection.
DR. HARRINGTON: What happens to GFR when INF-a is given
to non-renal transplant patients? Second, what accounts for any
difference?
DR. V0sNIDE5: Reduction of GFR is a rare complication of
INF-a therapy in non-transplant patients. I don't know the
mechanisms involved, but acute interstitial nephritis with ne-
phrotic syndrome similar to that in patients receiving nonsteroidal
anti-inflammatory drugs has been reported with INF-a therapy
[160]. Renal insufficiency, focal segmental mesangial prolifera-
tion, and proteinuria associated with an unusual histologic lesion
characterized by global, diffuse, and marked widening of the
lamina rara interna also have been observed in a patient receiving
long-term INF-a [161]. Furthermore, INF-a therapy has been
associated with isolated cases of membranoproliferative glomer-
ulonephritis accompanied by circulating and glomerular immune
complexes consisting of IgG antibody complexed to INF-u [162],
hemolytic-uremic syndrome [163], and rhabdomyolysis [164]. Re-
garding the second part of your question, I don't know what
accounts for the differences between renal transplant and non-
transplant patients.
DR. B0LETIs: You mentioned that less immunosuppression
could benefit the course of the liver disease. Should we avoid any
specific immunosuppressive drugs in HCV-infected renal trans-
plant recipients?
DR. VOSNIDES: Although we have no firm data, Morales et al
reported that the clinical course of HCV-infected renal transplant
recipients with chronic liver disease who were receiving cyclospor-
me A was better than that of renal transplant recipients receiving
azathioprine [82, 104]. Hestin and colleagues noted that among
renal transplant recipients with histologic evidence of chronic
hepatitis C, those with a Knodell's index of greater than 5 were
more frequently treated with azathioprine than those with a
Knodell's index of less than 5 [83]. Furthermore, Roth and
coworkers used logistic regression analysis to show that in RIBA-
positive renal transplant recipients, anti-lymphocyte globulin
treatment was a predictor of abnormal liver function [81].
DR. THEODORE MOUNTOKALAKIS (Chairman, Third Medical Dc-
partmen1, Medical School, University of Athens): Does the outcome
of hepatitis C virus differ between immunosuppressed and non-
immunosuppressed patients?
DR. V05NIDEs: There are no controlled data, but I think that in
non-immunosuppressed patients, hepatitis C has a more benign
course than in immunosuppressed patients. A large long-term
study compared the mortality rate of 568 subjects with post-
transfusion non-A, non-B hepatitis, who were identified in five
major prospective studies performed between 1967 and 1980, with
the mortality rate of control subjects who had received blood
transfusions but who did not have hepatitis [165]. Each study
patient was matched with two control subjects (first control group
and second control group). After an average followup of 18 years,
the mortality rate from all causes did not differ significantly among
the three groups (51%, 50%, and 52% for the hepatitis patients,
the first, and the second control group, respectively). Mortality
due to liver disease was slightly but significantly higher in the
patients with hepatitis (3.3%, 1.1%, and 2% for the patients, the
first, and the second control groups, respectively). Of the deaths
related to liver disease, 71% occurred in patients with chronic
alcoholism. This study contrasts sharply with that of Pereira et al,
who, as I said earlier, reported a 3.3-fold higher mortality rate and
a 9.9-fold higher incidence of death due to sepsis after renal
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transplantation in recipients who were anti-HCV-positive com-
pared with those who were anti-HCV-negative prior to transplan-
tatiOn [901. Furthermore, the increased risk of death in anti-HCV-
positive recipients was apparent within a relatively short period
after transplantation (median followup, 45 months). So it seems
that in immunosuppressed patients, hepatitis-C-related liver dis-
ease is more aggressive than in non-immunosuppressed patients.
DR. LEVEY: I agree. Previous studies on immunosuppression in
patients with chronic hepatitis B infection also disclosed that the
patients treated with prednisone did worse than those who did not
receive immunosuppression [1661.
DR. MADIAS: Dr. Levey, would you comment on the occurrence
of sepsis in patients with graft-related HCV liver disease? Was the
incidence of cytomegalovirus disease increased in these patients?
DR. LEVEY: Our study comparing hepatitis-C-positive versus
hepatitis-C-negative transplant recipients identified an increased
risk of death from sepsis in patients with hepatic disease [901.
Earlier work comparing the course of hepatitis-B-positive versus
hepatitis-B-negative patients after renal transplantation produced
the same finding [167]. What is the basis for the apparent
increased risk of infectious complications in renal transplant
patients with liver disease? I don't know. Clearly, the risk of
infection in patients with cirrhosis—independent of renal trans-
plant or the immunocompromised status—is increased, and this
might account for the finding. Regarding your second question,
we did not identify CMV infection as the cause of sepsis in the
patients we saw.
If I may make one other comment in response to Dr. Har-
rington's question. He asked specifically about data correlating
liver histology with fatal outcome in renal transplant recipients
with hepatitis C. I am not aware of such data, hut there are very
good data from 20 years ago correlating the extent of hepatic
pathologic changes and death from liver disease in patients with
hepatitis B but without renal disease [1681. There is no reason to
think that that relationship would be different in renal transplant
patients. I think these older data very strongly direct us to make
our prognosis from the results of liver biopsies. That is, the liver
biopsy stands up as a better marker of the severity of liver disease
than does the serum biochemical evidence.
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In Memoriam
Gregory G. Vosnides, M.D.
(1943—1996)
Born in 1943 in Alexandria, Egypt, of Greek parents, Dr. Vosnides
graduated from the Athens University School of Medicine in 1967.
He completed residency training in internal medicine and nephrology
in England (1967—1975), including a two-year tenure at Guy's Hos-
pital in London with Professor J. Stewart Cameron. Upon return to
his native Greece, he assumed supervisory staff positions at the
General State Hospital and the Evangelismos Hospital of Athens. In
1985, he was appointed Chief of the Division of Nephrology at the
Laiko General Hospital in Athens, a position he held until his death.
He was active as a clinician, researcher, and educator, having
supervised the specialty training of many nephrologists. Under his
leadership, the Division of Nephrology at the Laiko General Hospital
became one of the premier nephrology centers of Greece. Between
1994 and 1996, he served as President of the Hellenic Society of
Nephrology. Dr. Vosnides' clinical practice was characterized by a
high level of compassion for his patients. The editors of the Nephrol-
ogy Forum express our deepest condolences to the Vosnides family
and to the nephrology community of Greece.
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